Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials

European Radiology

Volumn 22, Issue 7, 2012, Pages 1465-1478

  Aboagye, Eric O ^a   Gilbert, Fiona J ^b   Fleming, Ian N ^c   Beer, Ambros J ^d   Cunningham, Vincent J ^e   Marsden, Paul K ^f   Visvikis, Dimitris ^g   Gee, Antony D ^f   Groves, Ashley M ^h   Kenny, Laura M ^a   Cook, Gary J ⁱ   Kinahan, Paul E ^j   Myers, Melvyn ^a   Clarke, Larry ^k  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF ABERDEEN   (United Kingdom)

^f ST THOMAS HOSPITAL   (United Kingdom)

^g CHU MORVAN   (France)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^j UNIVERSITY OF WASHINGTON   (United States)

^k Cancer Imaging Program   (United States)

more..

Author keywords

15O water; Angiogenesis; Integrin receptor ligand; Positron emission tomography; Tumour vascularity

Indexed keywords

5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; BEVACIZUMAB; CARBON MONOXIDE; EVEROLIMUS; FLUCICLATIDE F 18; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FLUOROURIDINE; INTEGRIN RECEPTOR; INTERFERON; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1,2,3 TRIAZOL 1 YL)ETHOXY] 4 QUINAZOLINAMINE; RADIOLIGAND; SUNITINIB; TRACER; WATER; ZIRCONIUM DERIVATIVE;

CELL SURFACE; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); HUMAN; IMAGING SYSTEM; MACROMOLECULE; PATHOPHYSIOLOGY; PHARMACODYNAMICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVIEW; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR VOLUME;

CLINICAL TRIALS AS TOPIC; EUROPE; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NORTH AMERICA; POSITRON-EMISSION TOMOGRAPHY; PRACTICE GUIDELINES AS TOPIC; RADIOPHARMACEUTICALS; REFERENCE STANDARDS;

EID: 84864718200     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-011-2311-3     Document Type: Review

References (93)

1. Workman P, Aboagye EO, Chung Y et al (2006) Minimally invasive pharmacokinetic and pharmacodynamic technologies in hypothesis-Testing clinical trials of innovative therapies. J Natl Cancer Inst 98:580-598
2. Lammertsma AA, Frackowiak RSJ, Hoffman JM et al (1989) The C15O2 build-up technique to measure regional cerebral blood flow and volume of distribution of water. J Cereb Blood Flow Metab 9:461-470
3. Hoekstra CJ, Stroobants SG, Hoekstra OS, Smit EF, Vansteenkiste JF, Lammertsma AA (2002) Measurement of perfusion in stage IIIA-N2 non-small cell lung cancer using H2 15O and positron emission tomography. Clin Cancer Res 8:2109-2115
4. Iida H, Rhodes CG, De Silva R et al (1992) Use of the left ventricular time-Activity curve as a noninvasive input function in dynamic oxygen-15-water positron emission tomography. J Nucl Med 33:1669-1677
5. De Langen AJ, Van Den Boogaart VEM, Marcus JT, Lubberink M (2008) Use of H2 15O-PET and DCE-MRI to measure tumor blood flow. Oncologist 13:631-644
6. Wilson CBJH, Lammertsma AA, McKenzie CG, Sikora K, Jones T (1992) Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: A rapid and noninvasive dynamic method. Cancer Res 52:1592-1597
7. Wells P, Jones T, Price P (2003) Assessment of inter-And intrapatient variability in C15O 2 positron emission tomography measurements of blood flow in patients with intra-Abdominal cancers. Clin Cancer Res 9:6350-6356
8. De Langen AJ, Lubberink M, Boellaard R et al (2008) Reproducibility of tumor perfusion measurements using15Olabeled water and PET. J Nucl Med 49:1763-1768
9. Lodge MA, Jacene HA, Pili R, Wahl RL (2008) Reproducibility of tumor blood flow quantification with15O-water PET. J Nucl Med 49:1620-1627
10. Burke D, Davies MM, Zweit J et al (2001) Continuous angiotensin II infusion increases tumour: Normal blood flow ratio in colo-rectal liver metastases. Br J Cancer 85:1640-1645
11. Taniguchi H, Koyama H, Masuyama M et al (1996) Angiotensin-II-induced hypertension chemotherapy: Evaluation of hepatic blood flow with oxygen-15 PET. J Nucl Med 37:1522-1523
12. Koh T, Taniguchi H, Yamagishi H (2003) Oxygen-15 positronemission tomography for predicting selective delivery of a chemotherapeutic agent to hepatic cancers during angiotensin IIinduced hypertension. Cancer Chemother Pharmacol 51:349-358
13. Anderson HL, Yap JT, Miller MP, Robbins A, Jones T, Price PM (2003) Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 21:2823-2830
14. Logan TF, Jadali F, Egorin MJ et al (2002) Decreased tumor blood flow as measured by positron emission tomography in cancer patients treated with interleukin-1 and carboplatin on a phase I trial. Cancer Chemother Pharmacol 50:433-444
15. Kötz B, West C, Saleem A, Jones T, Price P (2009) Blood flow and vd (water): Both biomarkers required for interpreting the effects of vascular targeting agents on tumor and normal tissue. Mol Cancer Ther 8:303-309
16. Herbst RS, Mullani NA, Davis DW et al (2002) Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 20:3804-3814
17. Anderson H, Yap JT, Wells P et al (2003) Measurement of renal tumour and normal tissue perfusion using positron emission tomography in a phase II clinical trial of razoxane. Br J Cancer 89:262-267
18. Saleem A, Yap J, Osman S et al (2000) Modulation of fluorouracil tissue pharmacokinetics by eniluracil: In-vivo imaging of drug action. Lancet 355:2125-2131
19. Harte RJA, Matthews JC, O'Reilly SM et al (1999) Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-Aspartate, folinic acid, and interferon alfa. J Clin Oncol 17:1580-1589
20. Gupta N, Saleem A, Kötz B et al (2006) Carbogen and nicotinamide increase blood flow and 5-fluorouracil delivery but not 5-fluorouracil retention in colorectal cancer metastases in patients. Clin Cancer Res 12:3115-3123
21. Kurdziel KA, Figg WD, Carrasquillo JA et al (2003) Using positron emission tomography 2-deoxy-2-[18F]fluoro-D-glucose, 11CO, and 15O-water for monitoring androgen independent prostate cancer. Mol Imaging Biol 5:86-93
22. Luurtsema G, Boellaard R, Greuter HNJM et al (2010) Pharmaceutical preparation of oxygen-15 labelled molecular oxygen and carbon monoxide gasses in a hospital setting. J Clin Pharm Ther 35:63-69
23. Mullani NA, Herbst RS, O'Neil RG, Gould KL, Barron BJ, Abbruzzese JL (2008) Tumor blood flow measured by PET dynamic imaging of first-pass 18F-FDG uptake: A comparison with 15O-labeled water-measured blood flow. J Nucl Med 49:517-523
24. Tseng J, Dunnwald LK, Schubert EK et al (2004) 18F-FDG kinetics in locally advanced breast cancer: Correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy. J Nucl Med 45:1829-1837
25. Zasadny KR, Tatsumi M, Wahl RL (2003) FDG metabolism and uptake versus blood flow in women with untreated primary breast cancers. Eur J Nucl Med Mol Imaging 30:274-280
26. Dunnwald LK, Gralow JR, Ellis GK et al (2008) Tumor metabolism and blood flow changes by positron emission tomography: Relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 26:4449-4457
27. Semple SIK, Gilbert FJ, Redpath TW et al (2004) The relationship between vascular and metabolic characteristics of primary breast tumours. Eur Radiol 14:2038-2045
28. Mankoff DA, Dunnwald LK, Gralow JR et al (2002) Blood flow and metabolism in locally advanced breast cancer: Relationship to response to therapy. J Nucl Med 43:500-509
29. Mankoff DA, Dunnwald LK, Gralow JR et al (2003) Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med 44:1806-1814
30. Jennens RR, Rosenthal MA, Lindeman GJ, Michael M (2004) Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von hippel-lindau syndrome. Urologic Oncology: Seminars and Original Investigations 22:193-196
31. Zhu Z, Li F (2008) Serial PET scans demonstrate the success and limitations of antiangiogenic treatment in a case of lung adenocarcinoma. Clin Nucl Med 33:635-637
32. Cai W, Chen K, Mohamedali KA et al (2006) PET of vascular endothelial growth factor receptor expression. J Nucl Med 47:2048-2056
33. Wang H, Cai W, Chen K et al (2007) A new PET tracer specific for vascular endothelial growth factor receptor 2. Eur J Nucl Med Mol Imaging 34:2001-2010
34. Nagengast WB, De Vries EG, Hospers GA et al (2007) In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 48:1313-1319
35. Beer AJ, Haubner R, Goebel M et al (2005) Biodistribution and pharmacokinetics of the avß 3-selective tracer 18F-galacto-RGD in cancer patients. J Nucl Med 46:1333-1341
36. Beer AJ, Haubner R, Sarbia M et al (2006) Positron emission tomography using [18F]galacto-RGD identifies the level of integrin avß3 expression in man. Clin Cancer Res 12:3942-3949
37. Beer AJ, Lorenzen S, Metz S et al (2008) Comparison of integrin avß3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: A PET study using 18Fgalacto-RGD and 18F-FDG. J Nucl Med 49:22-29
38. Kenny LM, Coombes RC, Oulie I et al (2008) Phase I trial of the positron-emitting arg-gly-Asp (RGD) peptide radioligand 18FAH111585 in breast cancer patients. J Nucl Med 49:879-886
39. Beer AJ, Grosu A, Carlsen J et al (2007) [18F]galacto-RGD positron emission tomography for imaging of avß3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 13:6610-6616
40. Hood JD, Cheresh DA (2002) Role of integrins in cell invasion and migration. Nat Rev Cancer 2:91-100
41. Schnell O, Krebs B, Carlsen J et al (2009) Imaging of integrin avß3 expression in patients with malignant glioma by [18F] galacto-RGD positron emission tomography. Neuro-Oncology 11:861-870
42. Haubner R, Weber WA, Beer AJ et al (2005) Noninvasive visualization of the activated avß3 integrin in cancer patients by positron emission tomography and [18F]galacto-RGD. PLoS Medicine 2:0244-0252
43. Morrison MS, Ricketts S, Barnett J, Cuthbertson A, Tessier J, Wedge SR (2009) Use of a novel arg-gly-Asp radioligand, 18FAH111585, to determine changes in tumor vascularity after antitumor therapy. J Nucl Med 50:116-122
44. Nagengast WB, de Korte MA, Oude Munnink TH et al (2010) 89Zrbevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 51:761-767
45. Meyer CR, Armato SG III, Fenimore CP et al (2009) Quantitative imaging to assess tumor response to therapy: Common themes of measurement, truth data, and error sources. Translational Oncology 2:198-210
46. Boellaard R (2009) Standards for PET image acquisition and quantitative data analysis. J Nucl Med 50:11S-20S
47. Doot RK, Scheuermann JS, Christian PE, et al. (2010) Instrumentation factors affecting variance and bias of quantifying tracer uptake with PET/CT. Medical Physics
48. Minn H, Zasadny KR, Quint LE, Wahl RL (1995) Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology 196:167-173
49. Weber WA, Ziegler SI, Thödtmann R, Hanauske A, Schwaiger M (1999) Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 40:1771-1777
50. Crippa F, Gavazzi C, Bozzetti F et al (1997) The influence of blood glucose levels on [18F]fluorodeoxyglucose (FDG) uptake in cancer: a pet study in liver metastases from colorectal carcinomas. Tumori 83:748-752
51. Roy F, Beaulieu S, Boucher L, Bourdeau I, Cohade C (2009) Impact of intravenous insulin on 18F-FDG PET in diabetic cancer patients. J Nucl Med 50:178-183
52. Cobelli C, Foster D, Toffolo G (2001) Tracer kinetic in biomedical research: from data to model. Kluwer Academic/Plenum, Boston
53. Fahey FH, Kinahan PE, Doot RK, Kocak M, Thurston H, Poussaint TY (2010) Variability in PET quantitation within a multicenter consortium. Med Phys 37:3660-3666
54. ICRP publication 106 (2008) Radiation dose to patients from radiopharmaceuticals-A third amendment to ICRP publication 53. Ann ICRP Publication 38:1-198
55. Stabin MG, Sparks RB, Crowe E (2005) OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 46:1023-1027
56. Kelloff GJ, Krohn KA, Larson SM et al (2005) The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res 11:7967-7985
57. Visvikis D, Cheze-LeRest C, Costa D, Bomanji J, Gacinovic S, Ell P (2001) Influence of OSEM and segmented attenuation correction in the calculation of standardised uptake values for [18F]FDG PET. Eur J Nucl Med 28:1326-1335
58. Krak NC, Boellaard R, Hoekstra OS, Twisk JWR, Hoekstra CJ, Lammertsma AA(2005) Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging 32:294-301
59. Lucignani G, Larson SM (2010) Doctor, what does my future hold? the prognostic value of FDG-PET in solid tumours. Eur J Nucl Med Mol Imaging 37:1032-1038
60. Wahl RL, Jacene H, Kasamon Y, Lodge MA (2009) From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med 50:122S-150S
61. Schelling M, Avril N, Nährig J et al (2000) Positron emission tomography using [18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18:1689-1695
62. Seol YM, Kwon BR, Song MK et al (2010) Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy. Acta Oncol 49:201-208
63. Chung MK, Jeong HS, Park SG et al (2009) Metabolic tumor volume of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts short-Term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res 15:5861-5868. doi:10.1158/1078-0432.CCR-08- 3290
64. Hyun SH, Choi JY, Shim YM et al (2010) Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma. Ann Surg Oncol 17:115-122
65. Larson SM, Erdi Y, Akhurst T et al (1999) Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. the visual response score and the change in total lesion glycolysis. Clinical Positron Imaging (Netherlands) 2:159-171
66. Francis RJ, Byrne MJ, Van Der Schaaf AA et al (2007) Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans. J Nucl Med 48:1449-1458
67. Cazaentre T, Morschhauser F, Vermandel M et al (2010) Pretherapy 18F-FDG PET quantitative parameters help in predicting the response to radioimmunotherapy in non-hodgkin lymphoma. Eur J Nucl Med Mol Imaging 37:494-504
68. Erdi YE, Mawlawi O, Larson SM et al (1997) Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer 80:2505-2509
69. Daisne J, Sibomana M, Bol A, Doumont T, Lonneux M, Grégoire V (2003) Tri-dimensional automatic segmentation of PET volumes based on measured source-To-background ratios: influence of reconstruction algorithms. Radiother Oncol 69:247-250
70. Nestle U, Kremp S, Schaefer-Schuler A et al (2005) Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J Nucl Med 46:1342-1348
71. El Naqa I, Yang D, Apte A et al (2007) Concurrent multimodality image segmentation by active contours for radiotherapy treatment planning. Med Phys 34:4738-4749
72. Hatt M, Cheze le Rest C, Turzo A, Roux C, Visvikis D (2009) A fuzzy bayesian locally adaptive segmentation approach for volume determination in PET. IEEE Trans Med Imaging 28:881-893
73. Geets X, Lee JA, Bol A, Lonneux M, Grégoire V (2007) A gradient-based method for segmenting FDG-PET images: meth-odology and validation. Eur J Nucl Med Mol Imaging 34:1427-1438
74. Montgomery DWG, Amira A, Zaidi H (2007) Fully automated segmentation of oncological PET volumes using a combined multiscale and statistical model. Med Phys 34:722-736
75. Hatt M, Bailly P, Turzo A, Roux C, Visvikis D (2008) PET functional volume segmentation: a robustness study. IEEE Nuclear Science Symposium Conference Record:4335-4339
76. Minn H, Clavo AC, Grenman R, Wahl RL (1995) In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck. J Nucl Med 36:252-258
77. Nahmias C, Wahl LM (2008) Reproducibility of standardized uptake value measurements determined by 18F-FDG PET in malignant tumors. J Nucl Med 49:1804-1808
78. Paquet N, Albert A, Foidart J, Hustinx R (2004) Within-patient variability of 18F-FDG: standardized uptake values in normal tissues. J Nucl Med 45:784-788
79. Velasquez LM, Boellaard R, Kollia G et al (2009) Repeatability of 18F-FDG PET in a multicenter phase I study of patients with advanced gastrointestinal malignancies. J Nucl Med 50:1646-1654
80. De Langen AJ, Klabbers B, Lubberink M et al (2009) Reproducibility of quantitative 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography. Eur J Nucl Med Mol Imaging 36:389-395
81. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO (2007) Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 34:1339-1347
82. Hatt M, Cheze-Le Rest C, Aboagye EO et al (2010) Reproducibility of 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET tumor volume measurements. Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine 51:1368-1376
83. Doot R, Allberg K, Kinahan P (2010) Errors in serial PET SUV measurements. J Nucl Med 51:126P
84. Boellaard R, O'Doherty MJ, Weber WA et al (2010) FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 37:181-200
85. Kinahan PE, Doot RK, Wanner-Roybal M et al (2009) PET/CT assessment of response to therapy: tumor change measurement, truth data, and error. Translational Oncology 2:223-230
86. Clarke LP, Croft BS, Nordstrom R, Zhang H, Kelloff G, Tatum J (2009) Quantitative imaging for evaluation of response to cancer therapy. Translational Oncology 2:195-197
87. Lockhart CM, MacDonald LR, Alessio AM et al (2009) Minimizing instrument calibration error to reduce the effect of variability on PET/CT SUV measurements. J Nucl Med 50:61P
88. Zimmerman BE, Kinahan PE, Galbraith W, Allberg K, Mawlawi O (2009) Multicenter comparison of dose calibrator accuracy for PET imaging using a standardized source. J Nucl Med 50:123P
89. Innis RB, Cunningham VJ, Delforge J et al (2007) Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533-1539
90. Liu C, Pierce Ii LA, Alessio AM, Kinahan PE (2009) The impact of respiratory motion on tumor quantification and delineation in static PET/CT imaging. Phys Med Biol 54:7345-7362
91. Nehmeh SA, Erdi YE (2008) Respiratory motion in positron emission tomography/computed tomography: a review. Semin Nucl Med 38:167-176
92. Kinahan PE, Hasegawa BH, Beyer T (2003) X-ray-based attenuation correction for positron emission tomography/computed tomography scanners. Semin Nucl Med 33:166-179
93. Pan T, Sun X, Luo D (2007) Improvement of the cine-CT based 4D-CT imaging. Med Phys 34:4499-4503